Opinion

Video

Venetoclax-Based Treatment Clinical Trial Updates

Author(s):

Yuliya P.L Linhares, MD,Josie Montegaard, MSN, AGPCNP-BC

Yuliya Linhares, MD, discusses the CLL14 study, which is looking at venetoclax plus obinutuzumab in patients with previously untreated chronic lymphocytic leukemia.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
A variant in the IL-7 gene may predict which patients with kidney cancer are more likely to experience side effects from immunotherapy.
Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Image of man with brown hair.
Related Content
Adding casdatifan to Cabometyx showed encouraging activity and in previously treated ccRCC: © stock.adobe.com.
July 23rd 2025

Welireg Plus Cabometyx Shows Tumor Control in Kidney Cancer Trial

Tim Cortese
Adding casdatifan to Cabometyx therapy showed encouraging activity and was generally well tolerated in previously treated clear cell renal cell carcinoma.
A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More
January 22nd 2024

A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More

Alex Biese Brielle Benyon
We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.
Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed advanced EGFR-mutated lung cancer: © stock.adobe.com.
July 22nd 2025

Can Tagrisso Plus Chemo Help Patients With Lung Cancer Live Longer?

Spencer Feldman
Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed advanced EGFR-mutated lung cancer.
CURE Talks Cancer podcast
December 31st 2020

The Treatment Journey of a Patient with CLL

Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Mark Hoffman, a patient with chronic lymphocytic leukemia, about his diagnosis and treatment journey.
fda sign.
July 1st 2025

Therapies Which Received FDA Approval in July: What You Should Know

Ryan Scott
Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology indications and cancer types.
Linda Cohen is a survivor of small lymphocytic lymphoma and was diagnosed in 2009. Catch up on all of Linda's blogs here!
July 1st 2025

A Cocktail and the Freedom I Never Expected With Cancer

Linda Cohen
After years off medication, I finally enjoyed a grapefruit cocktail — symbolizing freedom from cancer’s constant shadow and hope for the future.